Open AccessEstablishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
Author(s) -
Fangfang Duan,
Cailu Song,
Yuyu Ma,
Kuikui Jiang,
Fei Xu,
Xiwen Bi,
Jiajia Huang,
Ruoxi Hong,
Zhangzan Huang,
Qianyi Lu,
Zhongyu Yuan,
Shusen Wang,
Xiaozhong Wen
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s314723
Subject(s) - nomogram , medicine , everolimus , oncology , metastatic breast cancer , proportional hazards model , breast cancer , multivariate analysis , hazard ratio , population , confidence interval , cancer , environmental health
There are no clinically available prognostic models for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer treated with everolimus. We aimed to develop a tool to predict the progression-free survival (PFS) and overall survival (OS) of these patients and to identify optimal candidates who would benefit from everolimus-based treatment in this heterogeneous patient population.